External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology 2025 ASCO® Annual Meeting
Roche and Genentech at

2025 ASCO® Annual Meeting

May 30 - June 03
Chicago, USA / Virtual (Hybrid)
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
01:42 PM
Duration 6mins United States
Fixed duration subcutaneous (SC) mosunetuzumab▼ (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): interim results from the Phase II MorningSun study
Flinn IW, Burke JM, Sharman JP, Anz B, Zuniga R, Tun AM, Jani P, Biondo JML, Wu M, Mun Y, Chopra VS, Farighi R, Lin T, Villasboas JC, Budde LE
Oncology - Haematology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 180mins Chicago, USA
Updated Efficacy and Safety of Entrectinib▼ in Children with Extracranial Solid or Primary Central Nervous System (CNS) Tumors Harboring ROS1 Fusions
A. Desai, H. Wang, E. Basu, M. Casanova, A. Armstrong, D. Morgenstern, C. Pratilas, A. Cardenas, T. Barata, C. E. Devlin, K. E. Hutchinson, F. Wu, J. Wulff, A. Gajjar, E. Fox
Oncology | Solid Tumours

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
Risk factors (RF) for brain metastases (BM) in patients (pts) with metastatic breast cancer (MBC): An analysis of US electronic health records (EHRs)
Leone JP, Sammons S.L, Lamert P, Huang Y, Montemurro F, Shivhare M, Restuccia E, Knott A, Sanglier T, Tolaney S.M, Lin N.U
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
Preliminary Safety, Pharmacokinetics, and Clinical Activity of Mosperafenib (RG6344) in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer
E. Fontana, M. Vieito, E. Castanon, I. Matos, O. Bechter, I. Moreno, C. Han, RL. Eefsen, DJ. Pinato, R. Plummer, H. Prenen, G. Schnetzler, P. Pettazzoni, D. Dejardin, A. Keelara, E. Cinato, N. Flinn, NA. Kratochwil, A. Roller, N. Keshelava
Oncology | Gastrointestinal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 6mins United States
Glofitamab▼ plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2 year (yr) follow up of STARGLO
Abramson JS, Ku M, Hertzberg M, Fox CP, Herbaux C, Huang H-Q, Yoon DH, Kim WS, Zhang H, Abdulhaq H, Townsend W, Mulvihill E, Orellana-Noia V, Ta R, Huang H, Kallemeijn M, Belousov A, Bottos A, Lundberg L, Gregory G
Oncology - Haematology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:30 PM
Duration 180mins Chicago, USA
Krascendo 2: a phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC)
Skoulidis F, Solomon B, Popat S, Frost N, Heist R, Zhou C, Zarak Crnkovic M, Antic V, Prizant H, Mayo MC Meyenberg C, Keufer-Le Gall S
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
IMpower010: Genomic Profiling and Clinical Outcomes With Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer (eNSCLC)
Heather A. Wakelee, Enriqueta Felip, Caicun Zhou, Eric Vallières, Martin Reck, Nasser Altorki, Achim Rittmeyer, Tibor Csoszi, Ihor Vynnychenko, Antonio Chella, Velimir Gayevskiy, Wei Zou, Barbara Gitlitz, Marcus Ballinger, Elizabeth Bennett, Barzin Y. Nabet, Minu K. Srivastava
Oncology | Non-Small Cell Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:19 PM
Duration 12mins United States
Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2- LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts
Oliveira M, Accordino M, Cervantes A, Gambardella V, Hamilton E, Italiano A, Jhaveri K, Juric D, Kalinsky K, Krop I, Saura C, Schmid P, Turner N C, Varga A, Jin Y, Lim S, Royer-Joo S, Shankar N, Schutzman J, Bedard P
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 12mins United States
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)
Frank A. Sinicrope, Fang-Shu Ou, Dirk Arnold, Walter Peters, Robert J. Behrens, Christopher H. Lieu, Khalid Matin, Deirdre J. Cohen, Samara L. Potter, Wendy L. Frankel, Ardaman Shergill, Dennis Hsu, Anke C. Reinacher-Schick, Tyler Zemla, Clare A. Gatten, Eileen M. O'Reilly, Jeffrey A. Meyerhardt
Oncology | Gastrointestinal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 180mins Chicago, USA
Meeting diversity enrollment targets in IMbrave152/SKYSCRAPER-14, a global phase 3 study in patients with unresectable hepatocellular carcinoma (HCC)
Cotter C, Bhagat R, Bulhan H, Leon P, Lin L, Richie N, Sims R, Spahn J, Stamatis M, Yalovsky L, Zhu H, Ibrahim Y
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
Longitudinal Assessment From Liquid Biopsy of Mutations in CD20: A Pilot Study Using a PETE Enrichment Strategy
Tyler Landrith, Linlin Cao, Samantha Smith, Ruben van der Merwe, Corinna Lutterbeck, Carmelo Carlo-Stella, Michael J Dickinson, Martin Hutchings, Ulrich Schlecht, Antonio Sorrentino, Wei Yang, Patrick Bogard, Marina Bacac, Alessia Bottos
Oncology | Non-Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 180mins Chicago, USA
Giredestrant (G) with atezolizumab (ATEZO), and/or abemaciclib (ABEMA) in patients (pts) with ER+/HER2- locally advanced/metastatic BC (LA/mBC): Interim analysis (IA) from the phase I/II MORPHEUS Breast Cancer (BC) study
Oliveira M, Sonnenblick A, Stemmer S, Cortes Gion M, Im SAH, Bermejo De Las Heras B, Gal Yam E, Sohn JH, Wander S, Rugo HS, Park Y, Cahuzac C, Collier A, Ngo H, Retiere AC, Schwab R, Zhu J, Jung KH
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
Phase Ib study of inavolisib (INAVO) + weekly paclitaxel (wP) in patients (pts) with locally advanced/metastatic (LA/m) incurable solid tumors: Safety, pharmacokinetics (PK), and preliminary antitumor activity
S.A. IM, G. Alonso Casal, I. Moreno, R. Kristoffer, V. Gambardella, A. Italiano, S. Lim, S. Cheeti, P. Yu, A. Swat, F. Amair-Pinedo, D. Juric
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:30 PM
Duration 180mins Chicago, USA
Impact of proton pump inhibitor (PPI) pharmacogenomics (PGx) on toxicities associated with immune checkpoint inhibitor (ICI) therapy
Kennedy LC, Mohindra R, Sharpe JM, Mycroft SL, Balko JM, Chandler SG, Lyalina S
Oncology | Solid Tumours

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 PM
Duration 12mins Arie Crown Theater
Lurbinectedin + atezolizumab as first-line maintenance treatment in patients with extensive-stage small cell lung cancer: Primary results of the Phase 3 IMforte trial
L Paz-Ares, H Borghaei, S Liu, S Peters, R Herbst, K Stencel, M Majem, G Czyzewic, R Bernabe Caro, K H Lee, M Johnson, N Karadurmus, C Grohe, V Cuchelkar, V Graupner, M Kaul, L Lin, D Chakrabarti, K Bhatt, M Reck
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.